Bexagliflozin |
![]() Last updated: 15/09/2025 |
![]() |
(Not known by any other names) |
|
![]() |
|
A new animal drug used to improve glycemic control in otherwise healthy cats with diabetes mellitus | |
---|---|---|
|
Diabetes mellitus | |
|
Cats |
Approval status |
|
Not approved | |
---|---|---|
|
Not approved |
Chemical structure |
|
Bexagliflozin exhibits stereoisomerism due to multiple chiral centres in its molecular structure. It has five distinct chiral centres within the glucose-like moiety of the molecule. Additionally, impurities of bexagliflozin include alpha isomers and epimers at various carbon positions (e.g., C2, C3, C4), further confirming its isomeric complexity. | |
---|---|---|
|
C₂₄H₂₉ClO₇ | |
|
C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl | |
|
- | |
|
BTCRKOKVYTVOLU-SJSRKZJXSA-N | |
|
InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1 | |
|
Yes |
General status |
|
Antidiabetic drug; Medicinal drug | |
---|---|---|
|
C-glycosyl drug | |
|
- | |
|
- | |
|
Synthetic | |
|
As a SGLT2 inhibitor it helps lower blood glucose levels by increasing glucose excretion through urine | |
|
[Sodium-Glucose Transporter 2, Inhibitor] | |
|
118567-05-7 | |
|
- | |
|
- | |
|
- | |
|
25195624 | |
|
Insulins and analogues; Sodium-glucose co-transporter 2 (SGLT2) inhibitors | |
|
QA10BK08 | |
|
No | |
|
- | |
|
464.94 | |
|
- | |
|
(2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol | |
|
- | |
|
- | |
|
- | |
|
- | |
|
Commercial product is a pale yellow powdery solid |
Commercial |
|
|
|||
---|---|---|---|---|
|
Novel | |||
|
2021, first patent; 2022, first approval US | |||
|
|
|||
|
|
|||
|
Oral administration | |||
|
The production of bexagliflozin involves a multi-step synthetic route designed to construct its complex chiral structure. The process begins with the preparation of a protected tetrahydropyran intermediate, which is functionalized with a 4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl moiety. This intermediate is dissolved in a solvent mixture of dichloromethane and acetonitrile under a nitrogen atmosphere. A boron trifluoride ethyl ether complex is then added dropwise at sub-zero temperatures, followed by triethylsilane to facilitate selective reduction. The reaction mixture is carefully stirred and quenched with aqueous sodium bicarbonate, maintaining strict temperature control to avoid degradation. After phase separation and solvent removal, the crude product is purified through ethyl acetate extraction and ethanol crystallisation. | |||
|
Published GHG data is not available for most pharmaceuticals. However, according to industry, global averages suggest producing 1 kg of a typical active pharmaceutical ingredient can range from 10 to 100 kg CO₂e for small molecule drugs and potentially up to 1000 kg CO₂e for complex biologicals such as vaccines, depending on the drug type, its formulation, complexity of synthesis, solvent recovery, and energy sources used. |
|
![]() |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- |
Degradation |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- |
Soil adsorption and mobility |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- |
Fate indices |
|
|
|
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - |
Known metabolites |
None
|
![]() |
Terrestrial ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | |||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
- | |||||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - |
Aquatic ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - |
|
![]() |
General |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Bexagliflozin is mainly eliminated through faeces and urine | R4 R = Peer reviewed scientific publications 4 = Verified data |
- |
Health issues |
|
|
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
May cause weight loss Increased risk of ketoacidosis May cause antihypertensive effects Increased risk of female genital mycotic infections, urinary tract infections, and increased urination |
Handling issues |
|
|
|||
---|---|---|---|---|
|
Not explosive or oxidising | |||
|
- | |||
|
- | |||
|
- | |||
|
- | |||
|
Shelf-life is around 1 year. Store at room temperature and away from excess heat and moisture |
|
![]() |
|
|
||
---|---|---|---|
|
bexagliflozin | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
Record last updated: | 15/09/2025 |
Contact: | aeru@herts.ac.uk |
Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |